These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

42 related articles for article (PubMed ID: 22957829)

  • 1. Should early improvement be re-defined to better predict the maintenance of response in first-episode schizophrenia patients?
    Schennach R; Riesbeck M; Mayr A; Seemüller F; Maier W; Klingberg S; Heuser I; Klosterkötter J; Gastpar M; Schmitt A; Sauer H; Schneider F; Jäger M; Wölwer W; Gaebel W; Möller HJ; Riedel M
    Acta Psychiatr Scand; 2013 Jun; 127(6):474-81. PubMed ID: 22957829
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Depressive symptoms and their association with acute treatment outcome in first-episode schizophrenia patients: comparing treatment with risperidone and haloperidol.
    Riedel M; Mayr A; Seemüller F; Maier W; Klingberg S; Heuser I; Klosterkötter J; Gastpar M; Schmitt A; Sauer H; Schneider F; Gaebel W; Jäger M; Möller HJ; Schennach-Wolff R
    World J Biol Psychiatry; 2012 Jan; 13(1):30-8. PubMed ID: 21568628
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
    Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
    Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trajectories and antecedents of treatment response over time in early-episode psychosis.
    Levine SZ; Rabinowitz J
    Schizophr Bull; 2010 May; 36(3):624-32. PubMed ID: 18849294
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An early improvement threshold to predict response and remission in first-episode schizophrenia.
    Schennach-Wolff R; Seemüller FH; Mayr A; Maier W; Klingberg S; Heuser I; Klosterkötter J; Gastpar M; Häfner H; Sauer H; Schneider F; Gaebel W; Jäger M; Möller HJ; Riedel M
    Br J Psychiatry; 2010 Jun; 196(6):460-6. PubMed ID: 20513856
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimizing early prediction for antipsychotic response in schizophrenia.
    Chang YC; Lane HY; Yang KH; Huang CL
    J Clin Psychopharmacol; 2006 Dec; 26(6):554-9. PubMed ID: 17110810
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials.
    Citrome L; Meng X; Hochfeld M; Stahl SM
    Hum Psychopharmacol; 2012 Jan; 27(1):24-32. PubMed ID: 22161738
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An open, randomized, comparative study of efficacy and safety of risperidone and haloperidol in schizophrenia.
    Tamrakar SM; Nepal MK; Koirala NR; Sharma VD; Gurung CK; Adhikari SR
    Kathmandu Univ Med J (KUMJ); 2006; 4(2):152-60. PubMed ID: 18603890
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First generation antipsychotics switch with Risperidone in the treatment of chronic schizophrenic patients.
    Popović I; Ravanić D; Popović V; Vladejić S; Stanojević A; Stojanović M
    Psychiatr Danub; 2011 Dec; 23(4):384-8. PubMed ID: 22075740
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influencing factors and predictors of early improvement in the acute treatment of schizophrenia and schizophrenia spectrum disorder.
    Schennach-Wolff R; Meyer S; Seemüller F; Jäger M; Schmauss M; Laux G; Pfeiffer H; Naber D; Schmidt LG; Gaebel W; Klosterkötter J; Heuser I; Maier W; Lemke MR; Rüther E; Klingberg S; Gastpar M; Möller HJ; Riedel M
    J Psychiatr Res; 2011 Dec; 45(12):1639-47. PubMed ID: 21862035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized controlled trial of long-acting injectable risperidone vs continuation on oral atypical antipsychotics for first-episode schizophrenia patients: initial adherence outcome.
    Weiden PJ; Schooler NR; Weedon JC; Elmouchtari A; Sunakawa A; Goldfinger SM
    J Clin Psychiatry; 2009 Oct; 70(10):1397-406. PubMed ID: 19906343
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antipsychotic response in the first week predicts later efficacy.
    Giegling I; Porcelli S; Balzarro B; Andrisano C; Schäfer M; Möller HJ; Rujescu D; Serretti A
    Neuropsychobiology; 2012; 66(2):100-5. PubMed ID: 22814310
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological long-term treatment strategies in first episode schizophrenia--study design and preliminary results of an ongoing RCT within the German Research Network on Schizophrenia.
    Gaebel W; Möller HJ; Buchkremer G; Ohmann C; Riesbeck M; Wölwer W; Von Wilmsdorff M; Bottlender R; Klingberg S
    Eur Arch Psychiatry Clin Neurosci; 2004 Apr; 254(2):129-40. PubMed ID: 15146342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictors of response and remission in the acute treatment of first-episode schizophrenia patients--is it all about early response?
    Schennach-Wolff R; Jäger M; Mayr A; Meyer S; Kühn KU; Klingberg S; Heuser I; Klosterkötter J; Gastpar M; Schmitt A; Schlösser R; Schneider F; Gaebel W; Seemüller F; Möller HJ; Riedel M
    Eur Neuropsychopharmacol; 2011 May; 21(5):370-8. PubMed ID: 21255982
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Longitudinal studies of antisaccades in antipsychotic-naive first-episode schizophrenia.
    Harris MS; Reilly JL; Keshavan MS; Sweeney JA
    Psychol Med; 2006 Apr; 36(4):485-94. PubMed ID: 16388703
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Risperidone in the treatment of chronic schizophrenia: multicenter study comparative to haloperidol].
    López Ibor JJ; Ayuso JL; Gutiérrez M; Guimon J; Herraiz ML; Chinchilla A; Ayuso JL; González Pinto A; Eguiluz I; Fernández A
    Actas Luso Esp Neurol Psiquiatr Cienc Afines; 1996; 24(4):165-72. PubMed ID: 8984849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Symptom recurrence following intermittent treatment in first-episode schizophrenia successfully treated for 2 years: a 3-year open-label clinical study.
    Emsley R; Oosthuizen PP; Koen L; Niehaus DJ; Martinez G
    J Clin Psychiatry; 2012 Apr; 73(4):e541-7. PubMed ID: 22579160
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics.
    Lindenmayer JP; Eerdekens E; Berry SA; Eerdekens M
    J Clin Psychiatry; 2004 Aug; 65(8):1084-9. PubMed ID: 15323593
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early response to antipsychotic therapy as a clinical marker of subsequent response in the treatment of patients with first-episode psychosis.
    Stauffer VL; Case M; Kinon BJ; Conley R; Ascher-Svanum H; Kollack-Walker S; Kane J; McEvoy J; Lieberman J
    Psychiatry Res; 2011 May; 187(1-2):42-8. PubMed ID: 21168920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adverse effects of risperidone on spatial working memory in first-episode schizophrenia.
    Reilly JL; Harris MS; Keshavan MS; Sweeney JA
    Arch Gen Psychiatry; 2006 Nov; 63(11):1189-97. PubMed ID: 17088499
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.